MicroRNA-195 as a prognostic factor for cancer survival outcome in China: a meta-analysis

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer Am Cancer Soc. 2018;124:2785–2800. doi:10.1002/cncr.31551
   Google Scholar
• Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13:e249–e258. doi:10.1016/S1470-2045(12)70140-722652233
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12. doi:10.1016/j.ydbio.2006.08.02816989803
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233. doi:10.1016/j.cell.2009.01.00219167326
   PubMed Web of Science ®Google Scholar
• Flavin RJ, Smyth PC, Laios A, et al. Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol. 2009;22:197–205. doi:10.1038/modpathol.2008.13518677302
   PubMed Web of Science ®Google Scholar
• He JF, Luo YM, Wan XH, Jiang D. Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J Biochem Mol Toxicol. 2011;25:404–408. doi:10.1002/jbt.2039622190509
   PubMed Web of Science ®Google Scholar
• Yu W, Liang X, Li X, et al. MicroRNA-195: a review of its role in cancers. Oncotargets Ther. 2018;11:7109–7123. doi:10.2147/OTT.S183600
   PubMed Web of Science ®Google Scholar
• Chan B, Manley J, Lee J, Singh SR. The emerging roles of microRNAs in cancer metabolism. Cancer Lett. 2015;356:301–308. doi:10.1016/j.canlet.2014.10.01125451319
   PubMed Web of Science ®Google Scholar
• Liu B, Qu J, Xu F, et al. MiR-195 suppresses non-small cell lung cancer by targeting CHEK1. Oncotarget. 2015;6:9445–9456. doi:10.18632/oncotarget.325525840419
   PubMedGoogle Scholar
• Liu C, Guan H, Wang Y, et al. miR-195 inhibits EMT by targeting FGF2 in prostate cancer cells. PLoS One. 2015;10:e144073. doi:10.1371/journal.pone.0144073
   PubMed Web of Science ®Google Scholar
• Shen YH, Xie ZB, Yue AM, et al. Expression level of microRNA-195 in the serum of patients with gastric cancer and its relationship with the clinicopathological staging of the cancer. Eur Rev Med Pharmacol Sci. 2016;20:1283–1287.27097947
   PubMed Web of Science ®Google Scholar
• Wang X, Wang J, Ma H, Zhang J, Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol. 2012;29:919–927. doi:10.1007/s12032-011-9880-521390519
   PubMed Web of Science ®Google Scholar
• Yu S, Jing L, Yin XR, et al. MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget. 2017;8:99757–99771. doi:10.18632/oncotarget.2090929245938
   PubMedGoogle Scholar
• Sun N, Ye L, Chang T, Li X, Li X. microRNA-195-Cdc42 axis acts as a prognostic factor of esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7:6871–6879.25400770
   PubMed Web of Science ®Google Scholar
• Zhou Q, Han LR, Zhou YX, Li Y. MiR-195 suppresses cervical cancer migration and invasion through targeting Smad3. Int J Gynecol Cancer. 2016;26:817–824. doi:10.1097/IGC.0000000000000686
   PubMed Web of Science ®Google Scholar
• Deng Z, Wang Y, Fang X, et al. Research on miRNA-195 and target gene CDK6 in oral verrucous carcinoma. Cancer Gene Ther. 2017;24:282–288. doi:10.1038/cgt.2017.1828621315
   PubMed Web of Science ®Google Scholar
• Zhu J, Ye Q, Chang L, et al. Upregulation of miR-195 enhances the radiosensitivity of breast cancer cells through the inhibition of BCL-2. Int J Clin Exp Med. 2015;8:9142–9148.26309570
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Schmitz U, Wolkenhauer O, et al. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene. 2013;32:3175–3183. doi:10.1038/onc.2012.32422847610
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605. doi:10.1007/s10654-010-9491-z20652370
   PubMed Web of Science ®Google Scholar
• McInnes M, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319:388–396. doi:10.1001/jama.2017.1916329362800
   PubMed Web of Science ®Google Scholar
• Chaimani A, Mavridis D, Salanti G. A hands-on practical tutorial on performing meta-analysis with Stata. Evid Based Ment Health. 2014;17:111–116. doi:10.1136/eb-2014-10196725288685
   PubMedGoogle Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139–145. doi:10.1016/j.cct.2015.09.00226343745
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8. doi:10.1186/1745-6215-8-16
   PubMed Web of Science ®Google Scholar
• Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi:10.1136/bmj.315.7109.6299310563
   PubMed Web of Science ®Google Scholar
• Chen S, Wang L, Yao X, et al. miR-195-5p is critical in REG gamma-mediated regulation of wnt/beta-catenin pathway in renal cell carcinoma. Oncotarget. 2017;8:63986–64000. doi:10.18632/oncotarget.1925628969047
   PubMedGoogle Scholar
• Sun P, Wang L, Lu Y, et al. MicroRNA-195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways. Int J Oncol. 2016;49:1155–1163. doi:10.3892/ijo.2016.360827572273
   PubMed Web of Science ®Google Scholar
• Shuang Y, Li C, Zhou X, Huang YW, Zhang L. Expression of miR-195 in laryngeal squamous cell carcinoma and its effect on proliferation and apoptosis of Hep-2. Eur Rev Med Pharmacol Sci. 2017;21:3232–3238.28770960
   PubMed Web of Science ®Google Scholar
• Wang T, Ren Y, Liu R, et al. miR-195-5p suppresses the proliferation, migration, and invasion of oral squamous cell carcinoma by targeting TRIM14. Biomed Res Int. 2017;2017:7378148. doi:10.1155/2017/737814829204446
   PubMed Web of Science ®Google Scholar
• Zhou B, Sun C, Hu X, et al. MicroRNA-195 suppresses the progression of pancreatic cancer by targeting DCLK1. Cell Physiol Biochem. 2017;44:1867–1881. doi:10.1159/00048587629224010
   PubMedGoogle Scholar
• Dong H, Lei J, Ding L, et al. MicroRNA: function, detection, and bioanalysis. Chem Rev. 2013;113:6207–6233. 10.1021/acs.analchem.8b0324623697835
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang X, Huang Z, et al. Prognostic value of miR-21 in various cancers: an updating meta-analysis. PLoS One. 2014;9:e102413. doi:10.1371/journal.pone.010241325019505
   PubMed Web of Science ®Google Scholar
• Wang S, Hu J, Zhang D, et al. Prognostic role of microRNA-31 in various cancers: a meta-analysis. Tumor Biol. 2014;35:11639–11645. doi:10.1007/s13277-014-2492-x
   PubMedGoogle Scholar
• Yang X, Yu J, Yin J, et al. MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Pharmazie. 2012 Jul;67(7):645-51.
   Google Scholar
• Wang M, Zhang J, Tong L, et al. MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA. Int J Clin Exp Patho. 2015;8:14110–14120.
   Web of Science ®Google Scholar
• Han K, Chen X, Bian,N, et al. MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1. Oncotarget 2015;6:8875–8889. doi:10.18632/oncotarget.3560
   Google Scholar
• Su K, Zhang T, Wang Y, et al. Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer. World J Surg Oncol 2016;14:224. doi:10.1186/s12957-016-0980-8
   Google Scholar